Maclean Talks Payer Access and New Opportunities Arising From Cures 3037
During the recent ISPOR conference, Ross Maclean, Precision Health Economics’ SVP, Head of Medical, sat down to talk with Med Ad News’ Christiane Truelove on new opportunities for payer access in light of new FDA draft guidance around section 3037 of the 21st Century Cures Act. While Maclean is optimistic about broader, more relevant HCEI communication as a result of the new guidance, he is also cautious: “It’s interesting because when I speak to the clients, the lawyers always remind you that nobody has yet received a letter from FDA about 114, and nobody wants to be the first.”
To read the complete article in Med Ad News, please click here.
(starts on page 1, skips to page 6, continued on 7 and 8)
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.